JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy

Blood. 2021 Dec 30;138(26):2886-2889. doi: 10.1182/blood.2021013996.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Benzhydryl Compounds / adverse effects*
  • Benzhydryl Compounds / therapeutic use
  • Canagliflozin / adverse effects*
  • Canagliflozin / therapeutic use
  • Female
  • Glucosides / adverse effects*
  • Glucosides / therapeutic use
  • Humans
  • Janus Kinase 2 / genetics*
  • Male
  • Middle Aged
  • Polycythemia / chemically induced*
  • Polycythemia / genetics
  • Sodium-Glucose Transporter 2 Inhibitors / adverse effects*
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use

Substances

  • Benzhydryl Compounds
  • Glucosides
  • Sodium-Glucose Transporter 2 Inhibitors
  • Canagliflozin
  • dapagliflozin
  • JAK2 protein, human
  • Janus Kinase 2
  • empagliflozin